Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Dunedin Income Growth Underperforms FTSE All Share In Half Year

Mon, 21st Sep 2015 09:55

LONDON (Alliance News) - Dunedin Income Growth Investment Trust PLC Monday said it underperformed the FTSE All Share in the half year to end-July in what it called a "difficult short period".

The investment trust reported a fall in net asset value per share of 2.1% for the half year, whilst the FTSE All Share rose 2.8%.

During the period, the company took a new position in speciality chemicals manufacturer Elementis PLC, and added to its holdings in Ultra Electronics Holdings PLC, Inchcape PLC and Berendsen PLC. It exited miner South32 Ltd and reinvested the proceeds into South32's parent company BHP Billiton PLC.

"We suffered from our relative lack of small and mid-cap companies, euro weakness affecting the value of our overseas holdings and a number of large positions such as Cobham, Compass, AstraZeneca and Pearson reversing strong share price performances in the prior period with limited justification. We don't see at this stage any fundamental reason why we should not benefit from some significant recovery from these companies in the future," the trust said in a statement.

Shares in Dunedin Income Growth were up 0.1% at 228.00 pence Monday morning.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Copyright 2015 Alliance News Limited. All Rights Reserved.

Related Shares

More News
Today 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out...

2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for pr...

2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood canc...

29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negoti...

29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.